Therefore, our data suggest that pMSCs could be used to treat cancers by enhancing the anti-cancer activity of NK cells in vitro through different mechanisms that would involve IL-12, IL-18, and IFN-ɣ receptors, as well as TLR3 and IL1ra as we previously suggested for DPMSCs [19]. This evidence concerns the gene IL18 and cancer.